array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(25) "Gsk Consumer Health, Inc."
["slug"]=>
string(32) "4abba-us-gsk-consumer-health-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/8434ac9a-9bf2-4877-a3a0-a4039c237204"
["description"]=>
string(518) "GSK Consumer Healthcare is a global business that discovers, develops, and manufactures innovative consumer healthcare products. It is an associate of GlaxoSmithKline plc, one of the world's largest healthcare companies. GSK Consumer Healthcare aims to become one of the world's most innovative, best performing, and trusted healthcare companies. Their goal is to improve lives through scientific innovation, build category-defining brands, and become Pakistan's first and best Fast Moving Consumer Healthcare Company."
["address_street"]=>
string(28) "184 Liberty Corner Rd Ste 78"
["address_place"]=>
string(6) "Warren"
["address_region"]=>
string(10) "New Jersey"
["founding_date"]=>
string(10) "1994-02-28"
["website_domain"]=>
string(7) "gsk.com"
["website_url"]=>
string(19) "https://www.gsk.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(300)
["article_count"]=>
int(451)
}
["articles"]=>
array(6) {
[0]=>
array(7) {
["title_en"]=>
string(114) "The new European pharmaceutical legislation could improve access to medicines but a political consensus is lacking"
["snippet_en"]=>
string(104) "The review of European pharmaceutical legislation, proposed by the European Commission in April 2023,..."
["url"]=>
string(160) "https://www.infosalus.com/farmacia/noticia-nueva-legislacion-farmaceutica-europea-podria-mejorar-acceso-medicamentos-falta-consenso-politico-20240212153556.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/8af37388-ca63-40f4-9fd5-34f396234309"
["source"]=>
string(13) "infosalus.com"
["publication_date"]=>
string(10) "2024-02-12"
["categories"]=>
array(4) {
[0]=>
string(46) "Management of Legal and Regulatory Environment"
[1]=>
string(13) "Collaboration"
[2]=>
string(22) "EU Political Evolution"
[3]=>
string(11) "Legislation"
}
}
[1]=>
array(7) {
["title_en"]=>
string(83) "Legal Battle: GSK Sues Pfizer and BioNTech for COVID-19 Vaccine Patent Infringement"
["snippet_en"]=>
string(157) "GlaxoSmithKline (GSK) has filed a lawsuit against Pfizer and BioNTech in Delaware federal court, alleging that the companies’ COVID-19 vaccines, Comirnaty,"
["url"]=>
string(108) "https://newswherever.com/legal-battle-gsk-sues-pfizer-and-biontech-for-covid-19-vaccine-patent-infringement/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/5caeac9c-2562-45fe-bd7a-85cd8a9780a3"
["source"]=>
string(16) "newswherever.com"
["publication_date"]=>
string(10) "2024-02-04"
["categories"]=>
array(7) {
[0]=>
string(8) "Epidemic"
[1]=>
string(8) "Verdicts"
[2]=>
string(17) "Business Disputes"
[3]=>
string(46) "Management of Legal and Regulatory Environment"
[4]=>
string(21) "Intellectual Property"
[5]=>
string(10) "Litigation"
[6]=>
string(5) "Legal"
}
}
[2]=>
array(7) {
["title_en"]=>
string(65) "GSK Agrees to Settle Robitussin ‘Non-Drowsy’ False-Ad Lawsuit"
["snippet_en"]=>
string(209) "GSK Consumer Health Inc. and consumers who alleged it deceptively marketed Robitussin cough medicines as “non-drowsy” have agreed in principle to a classwide settlement, according to a recent court filing."
["url"]=>
string(111) "https://news.bloomberglaw.com/business-and-practice/gsk-agrees-to-settle-robitussin-non-drowsy-false-ad-lawsuit"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/b0397ad4-50dd-481b-af4d-b15cf41c99a7"
["source"]=>
string(16) "bloomberglaw.com"
["publication_date"]=>
string(10) "2023-11-20"
["categories"]=>
array(5) {
[0]=>
string(46) "Management of Legal and Regulatory Environment"
[1]=>
string(16) "Case Settlements"
[2]=>
string(15) "Business Ethics"
[3]=>
string(5) "Legal"
[4]=>
string(16) "Customer Welfare"
}
}
[3]=>
array(7) {
["title_en"]=>
string(67) "Robitussin Consumers Want ‘Non-Drowsy’ False-Ad Suit Reinstated"
["snippet_en"]=>
string(171) "Robitussin users told an appeals court that federal law doesn’t block their claims that GSK Consumer Health Inc. deceptively advertises “non-drowsy” cough medicines."
["url"]=>
string(124) "https://news.bloomberglaw.com/product-liability-and-toxics-law/robitussin-consumers-want-non-drowsy-false-ad-suit-reinstated"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/a03874df-9da5-494e-8135-b154c5ddc8b9"
["source"]=>
string(16) "bloomberglaw.com"
["publication_date"]=>
string(10) "2023-06-30"
["categories"]=>
array(4) {
[0]=>
string(8) "Verdicts"
[1]=>
string(46) "Management of Legal and Regulatory Environment"
[2]=>
string(17) "Consumer Behavior"
[3]=>
string(5) "Legal"
}
}
[4]=>
array(7) {
["title_en"]=>
string(6) "Detail"
["snippet_en"]=>
string(129) "Daily current reports on deals, personal details and proceedings from business consulting law firms and company legal departments"
["url"]=>
string(67) "https://www.lto.de/kanzleien-unternehmen/transfermarkt/detail/4521/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/952ca27b-4ccc-4631-8358-873793e931a4"
["source"]=>
string(6) "lto.de"
["publication_date"]=>
string(10) "2023-04-04"
["categories"]=>
array(2) {
[0]=>
string(46) "Management of Legal and Regulatory Environment"
[1]=>
string(5) "Legal"
}
}
[5]=>
array(7) {
["title_en"]=>
string(64) "GSK Consumer Health $6.5 Million Benefiber False Ad Deal Gets OK"
["snippet_en"]=>
string(200) "A $6.5 million nationwide class settlement between GSK Consumer Health Inc. and customers alleging it deceptively marketed certain Benefiber products got the initial nod from a New York federal court."
["url"]=>
string(106) "https://news.bloomberglaw.com/class-action/gsk-consumer-health-6-5-million-benefiber-false-ad-deal-gets-ok"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/277eca4d-d033-4ddd-ad76-f841866de55f"
["source"]=>
string(16) "bloomberglaw.com"
["publication_date"]=>
string(10) "2021-06-09"
["categories"]=>
array(4) {
[0]=>
string(10) "Litigation"
[1]=>
string(16) "Case Settlements"
[2]=>
string(46) "Management of Legal and Regulatory Environment"
[3]=>
string(5) "Legal"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(28)
}
[1]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(27)
}
[2]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(26)
}
[3]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(21)
}
[4]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(20)
}
[5]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(18)
}
[6]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(17)
}
[7]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(17)
}
[8]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(15)
}
[9]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(14)
}
[10]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(14)
}
[11]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(14)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(12)
}
[13]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(11)
}
[14]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(10)
}
[15]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(10)
}
[16]=>
array(2) {
["name"]=>
string(20) "Business Development"
["count"]=>
int(9)
}
[17]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(9)
}
[18]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(8)
}
[19]=>
array(2) {
["name"]=>
string(16) "Customer Welfare"
["count"]=>
int(7)
}
[20]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(7)
}
[21]=>
array(2) {
["name"]=>
string(19) "Economic Conditions"
["count"]=>
int(6)
}
[22]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(6)
}
[23]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(6)
}
[24]=>
array(2) {
["name"]=>
string(6) "Crisis"
["count"]=>
int(6)
}
[25]=>
array(2) {
["name"]=>
string(21) "Cultural developments"
["count"]=>
int(6)
}
[26]=>
array(2) {
["name"]=>
string(7) "Layoffs"
["count"]=>
int(6)
}
[27]=>
array(2) {
["name"]=>
string(10) "Divestment"
["count"]=>
int(6)
}
[28]=>
array(2) {
["name"]=>
string(24) "Employee Health & Safety"
["count"]=>
int(6)
}
[29]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(5)
}
}
}
4abba-us-gsk-consumer-health-inc
Gsk Consumer Health, Inc.
Location
New Jersey
Founded
1994-02-28
Website
https://www.gsk.com
Articles
451 Articles
Category
Pharmaceutical Preparations
Description
GSK Consumer Healthcare is a global business that discovers, develops, and manufactures innovative consumer healthcare products. It is an associate of GlaxoSmithKline plc, one of the world's largest healthcare companies. GSK Consumer Healthcare aims to become one of the world's most innovative, best performing, and trusted healthcare companies. Their goal is to improve lives through scientific innovation, build category-defining brands, and become Pakistan's first and best Fast Moving Consumer Healthcare Company.
GlaxoSmithKline (GSK) has filed a lawsuit against Pfizer and BioNTech in Delaware federal court, alleging that the companies’ COVID-19 vaccines, Comirnaty,
GSK Consumer Health Inc. and consumers who alleged it deceptively marketed Robitussin cough medicines as “non-drowsy” have agreed in principle to a classwide settlement, according to a recent court filing.
Robitussin users told an appeals court that federal law doesn’t block their claims that GSK Consumer Health Inc. deceptively advertises “non-drowsy” cough medicines.
A $6.5 million nationwide class settlement between GSK Consumer Health Inc. and customers alleging it deceptively marketed certain Benefiber products got the initial nod from a New York federal court.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.